Compare AU & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AU | NTRA |
|---|---|---|
| Founded | 1944 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 39.1B |
| IPO Year | 2023 | 2015 |
| Metric | AU | NTRA |
|---|---|---|
| Price | $97.76 | $315.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $119.00 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | $38.71 | $18.08 |
| Revenue Next Year | $2.89 | $19.65 |
| P/E Ratio | $23.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $52.05 | $152.62 |
| 52 Week High | $129.14 | $326.03 |
| Indicator | AU | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 69.65 | 68.92 |
| Support Level | $89.75 | $186.96 |
| Resistance Level | $113.70 | N/A |
| Average True Range (ATR) | 3.29 | 11.35 |
| MACD | 2.37 | 4.76 |
| Stochastic Oscillator | 89.16 | 84.68 |
Anglogold Ashanti PLC is an independent gold mining company. It has a diversified asset portfolio, including production from operations in eight countries (Argentina, Australia, Brazil, Egypt, Ghana, Guinea, the DRC, and Tanzania), supported by greenfield projects in the United States and Colombia. The company's main product is gold, which once mined, is processed into dore (unrefined gold bars) on site and then dispatched to precious metals refineries. Geographically, Anglogold generates maximum revenue from its operations in Africa (comprising operations at Kibali, Iduapriem, Obuasi, Siguiri, Geita, and Sukari mines), followed by Australia (including Sunrise Dam and Tropicana), and the Americas (comprising Cerro Vanguardia, AngloGold Ashanti Mineracao, and Serra Grande operations).
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.